Bristol Post-Accounting Focus Will Be On R&D Investment, Investor Relations
Executive Summary
Maximizing Bristol-Myers Squibb's R&D return on investment will be one of the biggest challenges facing the company as it comes out of its accounting reforms, CFO Andrew Bonfield said